Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
A Phase II Study of Ponatinib in Cohorts of Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
Sponsor: Ariad Pharmaceuticals
This PHASE2 trial investigates Adenocarcinoma of the Lung and Extensive Stage Small Cell Lung Cancer and is currently completed. Ariad Pharmaceuticals leads this study, which shows 12 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jan 2022 — Mar 2022 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Dec 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Dec 2018 — Dec 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Sep 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ariad Pharmaceuticals
- University of Colorado, Denver
For direct contact, visit the study record on ClinicalTrials.gov .